EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Viela Bio's Enterprise Value is $2,545.22 Mil.
Viela Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2020 was $-126.74 Mil. Therefore, Viela Bio's EV-to-FCF for today is -20.08.
The historical rank and industry rank for Viela Bio's EV-to-FCF or its related term are showing as below:
VIE's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 8.34 * Ranked among companies with meaningful EV-to-FCF only.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-21), Viela Bio's stock price is $53.01.
Viela Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was $-2.830. Therefore, Viela Bio's PE Ratio for today is At Loss.
Viela Bio EV-to-FCF Historical Data
The historical data trend for Viela Bio's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Viela Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viela Bio's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viela Bio's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Viela Bio's EV-to-FCF falls into.
Viela Bio's current Enterprise Value is $2,545.22 Mil.
Viela Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-126.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viela Bio (NAS:VIE) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Viela Bio's share price for today is $53.01.
Viela Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.830.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Viela Bio EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Viela Bio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VIE has been successfully added to your 